These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 27697975)

  • 1. Response to Targeted Therapy in BRAF Mutant Anaplastic Thyroid Cancer.
    Agarwal R; Wang J; Wilson K; Barrett W; Morris JC
    J Natl Compr Canc Netw; 2016 Oct; 14(10):1203-1207. PubMed ID: 27697975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rechallenge with dabrafenib plus trametinib in anaplastic thyroid cancer: A case report and review of literature.
    Arıkan R; Telli TA; Demircan NC; Başoğlu T; Ercelep Ö; Atasoy BM; Özgüven S; Dane F; Yumuk PF
    Curr Probl Cancer; 2021 Apr; 45(2):100668. PubMed ID: 33127167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in
    Wang JR; Zafereo ME; Dadu R; Ferrarotto R; Busaidy NL; Lu C; Ahmed S; Gule-Monroe MK; Williams MD; Sturgis EM; Goepfert RP; Gross ND; Lai SY; Gunn GB; Phan J; Rosenthal DI; Fuller CD; Morrison WH; Iyer P; Cabanillas ME
    Thyroid; 2019 Aug; 29(8):1036-1043. PubMed ID: 31319771
    [No Abstract]   [Full Text] [Related]  

  • 4. Case report: Complete response of an anaplastic thyroid carcinoma patient with
    Gui L; Zhu Y; Li X; He X; Ma T; Cai Y; Liu S
    Front Immunol; 2023; 14():1178682. PubMed ID: 37122752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in the management of anaplastic thyroid carcinoma: transforming a life-threatening condition into a potentially treatable disease.
    Califano I; Smulever A; Jerkovich F; Pitoia F
    Rev Endocr Metab Disord; 2024 Feb; 25(1):123-147. PubMed ID: 37648897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salutary Response to Targeted Therapy in Anaplastic Thyroid Cancer.
    Fazeli S; Paal E; Maxwell JH; Burman KD; Nylen ES; Khosla SG
    J Investig Med High Impact Case Rep; 2019; 7():2324709619890942. PubMed ID: 31766881
    [No Abstract]   [Full Text] [Related]  

  • 7. Initial Management of BRAF V600E-Variant Anaplastic Thyroid Cancer: The FAST Multidisciplinary Group Consensus Statement.
    Hamidi S; Dadu R; Zafereo ME; Ferrarotto R; Wang JR; Maniakas A; Gunn GB; Lee A; Spiotto MT; Iyer PC; Sousa LG; Akhave NS; Ahmed S; Learned KO; Lu C; Lai SY; Williams M; Hosseini SM; Busaidy NL; Cabanillas ME
    JAMA Oncol; 2024 Sep; 10(9):1264-1271. PubMed ID: 38990526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dabrafenib and Trametinib Therapy for Advanced Anaplastic Thyroid Cancer - Real-World Outcomes From UK Centres.
    Lorimer C; Cheng L; Chandler R; Garcez K; Gill V; Graham K; Grant W; Sardo Infirri S; Wadsley J; Wall L; Webber N; Wong KH; Newbold K
    Clin Oncol (R Coll Radiol); 2023 Jan; 35(1):e60-e66. PubMed ID: 36379836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of MEK Signaling Attenuates Cancer Stem Cell Activity in Anaplastic Thyroid Cancer.
    Kimura T; Doolittle WKL; Kruhlak M; Zhao L; Hwang E; Zhu X; Tang B; Wolcott KM; Cheng SY
    Thyroid; 2024 Apr; 34(4):484-495. PubMed ID: 38115586
    [No Abstract]   [Full Text] [Related]  

  • 10. Mutation based approaches to the treatment of anaplastic thyroid cancer.
    McCrary HC; Aoki J; Huang Y; Chadwick B; Kerrigan K; Witt B; Hunt JP; Abraham D
    Clin Endocrinol (Oxf); 2022 May; 96(5):734-742. PubMed ID: 35067961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic Alterations of Anaplastic Thyroid Carcinoma Detected by Targeted Massive Parallel Sequencing in a BRAF(V600E) Mutation-Prevalent Area.
    Jeon MJ; Chun SM; Kim D; Kwon H; Jang EK; Kim TY; Kim WB; Shong YK; Jang SJ; Song DE; Kim WG
    Thyroid; 2016 May; 26(5):683-90. PubMed ID: 26980298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF Inhibition in BRAFV600E-Positive Anaplastic Thyroid Carcinoma.
    Lim AM; Taylor GR; Fellowes A; Cameron L; Lee B; Hicks RJ; McArthur GA; Angel C; Solomon B; Rischin D
    J Natl Compr Canc Netw; 2016 Mar; 14(3):249-54. PubMed ID: 26957611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-Time Genomic Characterization Utilizing Circulating Cell-Free DNA in Patients with Anaplastic Thyroid Carcinoma.
    Sandulache VC; Williams MD; Lai SY; Lu C; William WN; Busaidy NL; Cote GJ; Singh RR; Luthra R; Cabanillas ME
    Thyroid; 2017 Jan; 27(1):81-87. PubMed ID: 27785980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pediatric, Adolescent, and Young Adult Thyroid Carcinoma Harbors Frequent and Diverse Targetable Genomic Alterations, Including Kinase Fusions.
    Vanden Borre P; Schrock AB; Anderson PM; Morris JC; Heilmann AM; Holmes O; Wang K; Johnson A; Waguespack SG; Ou SI; Khan S; Fung KM; Stephens PJ; Erlich RL; Miller VA; Ross JS; Ali SM
    Oncologist; 2017 Mar; 22(3):255-263. PubMed ID: 28209747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in anaplastic thyroid cancer management.
    Hamidi S; Maniakas A
    Curr Opin Endocrinol Diabetes Obes; 2023 Oct; 30(5):259-264. PubMed ID: 37410453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete response of metastatic
    Lee SJ; Song SY; Kim MK; Na HG; Bae CH; Kim YD; Choi YS
    World J Clin Cases; 2023 Sep; 11(27):6664-6669. PubMed ID: 37900238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Anaplastic thyroid carcinoma : new therapeutic approaches].
    Stamatiou A; Herrera-Gómez RG; Szturz P; Bisig B; Romano E; Sykiotis G; Gorostidi F; La Rosa S; Kopp P; Cristina V
    Rev Med Suisse; 2021 May; 17(739):962-966. PubMed ID: 34009754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutation-based, short-term "neoadjuvant" treatment allows resectability in stage IVB and C anaplastic thyroid cancer.
    Maurer E; Eilsberger F; Wächter S; Riera Knorrenschild J; Pehl A; Holzer K; Neubauer A; Luster M; Bartsch DK
    Eur Arch Otorhinolaryngol; 2023 Mar; 280(3):1509-1518. PubMed ID: 36637521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth arrest by activated BRAF and MEK inhibition in human anaplastic thyroid cancer cells.
    Kurata K; Onoda N; Noda S; Kashiwagi S; Asano Y; Hirakawa K; Ohira M
    Int J Oncol; 2016 Dec; 49(6):2303-2308. PubMed ID: 27748799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anaplastic thyroid cancer:Improved understanding of what remains a deadly disease.
    Cleere EF; Prunty S; O'Neill JP
    Surgeon; 2024 Feb; 22(1):e48-e53. PubMed ID: 37866980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.